Serious Pulmonary Toxicity Secondary to Novel Hepatitis C Antiviral Therapy in a Liver Transplant Recipient.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 26231293.
- Also identified by DOI 10.1016/j.mayocp.2015.06.015.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Historically, the treatment of hepatitis C virus infection has been difficult, but therapeutic options have improved markedly recently because of the development of novel antiviral therapies. These therapies have been well tolerated. We describe a patient who was receiving such therapy and had development of temporally related and histologically confirmed severe pulmonary toxicity. Pulmonary toxicity should be considered a potential serious complication of novel antiviral therapy for hepatitis C virus infection.
Medical subject headings
- Antiviral Agents
- Hepatitis C, Chronic
- Liver Transplantation
- Pulmonary Fibrosis